Pharmacodynamic Responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats

Bone

Volumn 50, Issue 6, 2012, Pages 1332-1342

  Fisher, John E ^a   Scott, Kevin ^a   Wei, Nan ^a   Zhao, Jing Z ^a   Cusick, Tara ^a   Tijerina, Monica ^a   Karanam, Bindhu ^a   Duong, Le ^a   Glantschnig, Helmut ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; CaSR; Osteoporosis; PTH; Secretagogue

Indexed keywords

ALENDRONIC ACID; CALCIUM; JTT 305; MK 5442; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE DENSITY; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; FEMUR; LONG TERM CARE; LUMBAR VERTEBRA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OSSIFICATION; OSTEOPENIA; OVARIECTOMY; PARATHYROID HORMONE BLOOD LEVEL; PHARMACODYNAMICS; RAT; TIBIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALENDRONATE; ANIMALS; BENZOATES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; OVARIECTOMY; PARATHYROID HORMONE; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCIUM-SENSING;

EID: 84860840427     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.03.004     Document Type: Article

References (42)

1. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344(1):1434-1441.
2. Deal C. The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr Rheumatol Rep 2004, 6:49-58.
3. Saag K.G., Shane E., Boonen S., Marin F., Donley D.W., Taylor K.A., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357(1):2028-2039.
4. Greenspan S.L., Bone H.G., Ettinger M.P., Hanley D.A., Lindsay R., Zanchetta J.R., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146:326-339.
5. Finkelstein J.S., Wyland J.J., Leder B.Z., Burnett-Bowie S.M., Lee H., Juppner H., et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009, 94:2495-2501.
6. Girotra M., Rubin M.R., Bilezikian J.P. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006, 7:113-121.
7. Brown E.M., Macleod R.J. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001, 81:239-297.
8. Messa P., Alfieri C., Brezzi B. Cinacalcet: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol 2008, 4:1551-1560.
9. Nemeth E.F., DelMar E.G., Heaton W.L., Miller M.A., Lambert L.D., Conklin R.L., et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther 2001, 299(4):323-331.
10. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., Gordon D.N., Papapoulos S., Bone H.G., et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2011, 96:2441-2449.
11. John M., Harfst E., Loeffler J., Belleli R., Zack J., Ruckle J., et al. A 4-week study of AXT914, a novel calcilytic compound for oral bone anabolic osteoporosis therapy, in postmenopausal women. J Bone Miner Res 2010, 25(Suppl. 1).
12. John M.R., Widler L., Gamse R., Buhl T., Seuwen K., Breitenstein W., et al. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone 2011, 49:233-241.
13. Kumar S., Matheny C.J., Hoffman S.J., Marquis R.W., Schultz M., Liang X., et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 2010, 46:534-542.
14. Shinagawa Y., Inoue T., Kasushima T., Kihuchi T., Ikenogami T., Ogawa N., et al. Discovery of a potent and short-acting oral calcilytic with pulsatile secretion of parathyroid hormone. ACS Med Chem Lett 2011, 2:238-242.
15. Fukumoto S., Nakamura T., Nishizawa Y., Hayahi M., Matsumoto T. Randomized, single-blinded placebo-controlled study of a novel calcilytic, JTT-305, in patients with postmenopausal osteoporosis. J Bone Miner Res 2009, 24:S40.
16. Kimura S., Nakagawa T., Matsuo Y., Ishida Y., Okamoto Y., Hayashi M. JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats. Eur J Pharmacol 2011, 668:331-336.
17. Fukumoto S., Nakamura T., Nishizawa Y., Matsumoto T. Randomized, double-blinded placebo-controlled study of a calcilytic compound, JTT-305, in patients with postmenopausal osteoporosis. Bone 2011, 48(Suppl. 2):S76.
18. Frolik C.A., Black E.C., Cain R.L., Satterwhite J.H., Brown-Augsburger P.L., Sato M., et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003, 33:372-379.
19. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
20. Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
21. Cosman F., Nieves J.W., Zion M., Barbuto N., Lindsay R. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 2008, 19:529-535.
22. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
23. Cosman F., Wermers R.A., Recknor C., Mauck K.F., Xie L., Glass E.V., et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009, 94(1):3772-3780.
24. Gowen M., Stroup G.B., Dodds R.A., James I.E., Votta B.J., Smith B.R., et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000, 105:1595-1604.
25. Ma Y.L., Bryant H.U., Zeng Q., Schmidt A., Hoover J., Cole H.W., et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2003, 144(10):2008-2015.
26. Seedor J.G., Quartuccio H.A., Thompson D.D. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 1991, 6(3):339-346.
27. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2(1):595-610.
28. Fox J., Miller M.A., Stroup G.B., Nemeth E.F., Miller S.C. Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion. Bone 1997, 21:163-169.
29. Girard P., Boissel J.P. Clockwise hysteresis or proteresis. J Pharmacokinet Biopharm 1989, 17:401-402.
30. Jee W.S., Yao W. Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact 2001, 1:193-207.
31. Rodan G.A., Seedor J.G., Balena R. Preclinical pharmacology of alendronate. Osteoporos Int 1993, 3(Suppl. 3):S7-S12. 11.
32. Fox J., Miller M.A., Newman M.K., Metcalfe A.F., Turner C.H., Recker R.R., et al. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 2006, 79:262-272.
33. Kimmel D.B., Bozzato R.P., Kronis K.A., Coble T., Sindrey D., Kwong P., et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993, 132:1577-1584.
34. Hayashi M., Nakagawa T., Maekawa M., Kimura S. The effect of JTT-305/MK-5442 an orally active calcium-sensing receptor antagonist on calcium metabolism in parathyroidectomized rats. J Bone Miner Res 2011, 26:S280.
35. Kantham L., Quinn S.J., Egbuna O.I., Baxi K., Butters R., Pang J.L., et al. The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Endocrinol Metab 2009, 297:E915-E923.
36. Chang W., Tu C., Chen T.H., Bikle D., Shoback D. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal 2008, 1:ra1.
37. 2+-sensing receptor regulates bone development, mineralization, and turnover. J Bone Miner Res 2011, 26:2935-2947.
38. Shu L., Ji J., Zhu Q., Cao G., Karaplis A., Pollak M.R., et al. The calcium-sensing receptor mediates bone turnover induced by dietary calcium and parathyroid hormone in neonates. J Bone Miner Res 2011, 26(2):1057-1071.
39. Martin T.J., Sims N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005, 11(22):76-81.
40. Pierroz D.D., Bonnet N., Baldock P.A., Ominsky M.S., Stolina M., Kostenuik P.J., et al. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 2010, 285(2):28164-28173.
41. Lauritzen D.B., Balena R., Shea M., Seedor J.G., Markatos A., Le H.M., et al. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J Bone Miner Res 1993, 8(1):871-879.
42. Leu C.T., Luegmayr E., Freedman L.P., Rodan G.A., Reszka A.A. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006, 38(1):628-636.